A detailed history of Parallel Advisors, LLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 50 shares of RGNX stock, worth $381. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50
Previous 50 -0.0%
Holding current value
$381
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

May 20, 2024

SELL
$17.23 - $21.71 $68 - $86
-4 Reduced 7.41%
50 $0
Q2 2023

Aug 04, 2023

SELL
$17.23 - $21.71 $68 - $86
-4 Reduced 7.41%
50 $0
Q1 2023

May 20, 2024

BUY
$18.08 - $24.55 $72 - $98
4 Added 8.0%
54 $1,000
Q3 2022

Nov 10, 2022

SELL
$22.29 - $35.04 $156 - $245
-7 Reduced 11.48%
54 $1,000
Q2 2022

Aug 01, 2022

BUY
$19.35 - $35.04 $212 - $385
11 Added 22.0%
61 $2,000
Q1 2022

Apr 28, 2022

SELL
$24.62 - $34.31 $443 - $617
-18 Reduced 26.47%
50 $2,000
Q4 2021

Jan 20, 2022

SELL
$30.19 - $40.28 $1,841 - $2,457
-61 Reduced 47.29%
68 $2,000
Q3 2021

Nov 02, 2021

BUY
$29.09 - $45.68 $1,832 - $2,877
63 Added 95.45%
129 $5,000
Q2 2021

Aug 06, 2021

BUY
$32.46 - $40.48 $519 - $647
16 Added 32.0%
66 $3,000
Q1 2020

Apr 27, 2020

BUY
$21.5 - $54.2 $1,075 - $2,710
50 New
50 $1,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $329M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.